Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:42:41.027Z.
Calculation as of: 2026-10-06T19:42:41.027Z.
Quote observation: 2026-10-06T19:40:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b447d722f006e82d19b5d98ef6acffd249f934693947ae19b5e437b2b2585766
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$516.33M
PS Ratio
16655.76
TTM Avg
14908.47
3Y Avg
10316.98
5Y Avg
6997.34
Market Cap
$538.80M
PS Ratio
2.25
TTM Avg
5.40
3Y Avg
94.65
5Y Avg
94.65
Market Cap
$511.18M
PS Ratio
62.20
TTM Avg
55.76
3Y Avg
22.85
5Y Avg
49.57
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $525.16M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $527.99M | 5.53 | 5.23 | 17.66 | 17.71 |
| Immix Biopharma, Inc. (IMMX)vs › | $528.79M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $529.60M | 647.43 | 390.36 | 569.23 | 569.23 |
| Altimmune, Inc. (ALT)vs › | $516.33M | 16655.76 | 14908.47 | 10316.98 | 6997.34 |
| Shattuck Labs, Inc. (STTK)vs › | $535.91M | 535.91 | 520.33 | 228.10 | 183.31 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $538.80M | 2.25 | 5.40 | 94.65 | 94.65 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $511.18M | 62.20 | 55.76 | 22.85 | 49.57 |
| Monopar Therapeutics Inc. (MNPR)vs › | $539.25M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $504.56M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-11 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
